Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

STREPTOMYCIN TREATMENT IN TULAREMIA

STREPTOMYCIN TREATMENT IN TULAREMIA From recent laboratory studies it is apparent that streptomycin exerts a strong bacteriostatic and bactericidal action on Pasteurella tularensis (commonly known as Bacterium tularense) in vivo1 as well as in vitro.2 One report3 has appeared suggesting that this antibiotic is effective against tularemia in human beings. The 7 cases reported here resulted from a laboratory acquired infection with Past. tularensis. The Schu strain4 was the one in widest use in the laboratory and was maintained at maximum virulence by frequent passage through mice and rabbits. Four patients (group I) were treated with streptomycin in the early stage of illness, and 3 (group II) were treated late in convalescence. All received the Foshay tularemia vaccine5 at some time prior to their illness, which may have been modified thereby. These cases are to be included in another report6 dealing with vaccine prophylaxis for tularemia. CLINICAL MATERIAL http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

STREPTOMYCIN TREATMENT IN TULAREMIA

JAMA , Volume 132 (4) – Sep 28, 1946

Loading next page...
 
/lp/american-medical-association/streptomycin-treatment-in-tularemia-mG8ZcDdI6s

References (4)

Publisher
American Medical Association
Copyright
Copyright © 1946 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1946.02870390011003
Publisher site
See Article on Publisher Site

Abstract

From recent laboratory studies it is apparent that streptomycin exerts a strong bacteriostatic and bactericidal action on Pasteurella tularensis (commonly known as Bacterium tularense) in vivo1 as well as in vitro.2 One report3 has appeared suggesting that this antibiotic is effective against tularemia in human beings. The 7 cases reported here resulted from a laboratory acquired infection with Past. tularensis. The Schu strain4 was the one in widest use in the laboratory and was maintained at maximum virulence by frequent passage through mice and rabbits. Four patients (group I) were treated with streptomycin in the early stage of illness, and 3 (group II) were treated late in convalescence. All received the Foshay tularemia vaccine5 at some time prior to their illness, which may have been modified thereby. These cases are to be included in another report6 dealing with vaccine prophylaxis for tularemia. CLINICAL MATERIAL

Journal

JAMAAmerican Medical Association

Published: Sep 28, 1946

There are no references for this article.